c-LEcta, an international supplier of enzymes for the biopharmaceutical industry, has launched the GMP-grade version of Denarase High Salt, a strategic extension of its Denarase portfolio.

The GMP-grade version of Denarase High Salt is intended to serve customers with clinical and commercial stage processes that require compliance with the highest quality standards.

Denarase High Salt is utilized for the removal of DNA/RNA impurities in biopharmaceutical production. It is an engineered version of c-LEcta’s top-selling product Denarase and was designed for improved salt and pH tolerance, enabling customers more flexibility in process development.

The launch of Denarase High Salt GMP-grade marks a significant milestone in c-LEcta’s commitment to providing innovative solutions for the biopharmaceutical industry. This engineered enzyme efficiently and cost-effectively removes nucleic acids in biomanufacturing processes that benefit from elevated salt levels. Key applications include: 

• Viral Vectors for Cell & Gene Therapies 
• Viral Vaccines 
• Viscosity reduction in Lysates 
• Sample preparation in Electrophoresis and Chromatography